In 2019, a company named Peptide Clinics Australia was fined $10m for advertising schedule 4 substances, including by displaying them for purchase on a part of its website that was accessible to customers after they had completed a health questionnaire
Protocol approach 2: gut-focused autoimmune support (BPC-157 plus KPV) Goal: Restore gut barrier integrity and reduce intestinal inflammation Components: BPC-157 : 200-300 mcg twice daily, orally or subcutaneously near the abdomen (promotes mucosal healing, angiogenesis) KPV: 200-500 mcg daily, orally (NF-kB inhibition, cytokine reduction, PepT1-mediated gut absorption) Rationale: For autoimmune conditions with significant gastrointestinal involvement, including IBD, celiac-associated inflammation, or any autoimmune condition complicated by leaky gut, this combination addresses both the physical barrier damage (BPC-157) and the inflammatory signaling (KPV)
Although custom orthotics are more expensive than off-the-shelf devices, they last much longer and provide more individualized support and correction
While more large-scale human studies are needed, current research and clinical use suggest that BPC-157 is well tolerated and low-risk when used under medical supervision
